Trichosporon beigelii infection: experience in a regional burn center.
Trichosporon beigelii is a fungus once thought to cause only superficial infections, but recently has been increasingly identified as an opportunistic systemic pathogen in immunocompromised patients. There have been very limited reports of this organism in the burn patient population. We describe the first report of pharmacological management of invasive T. beigelii with a combination of amphotericin B and high dose fluconazole in a burn patient. Antifungal susceptibility testing of T. beigelii determined a change in minimum inhibitory concentrations (MICs) of amphotericin B and a consistent resistance pattern with the use of flucytosine. This paper will review our experience with T. beigelii fungus in a regional burn treatment center and review the literature on other experiences in the burn population.
Cawley
M J
MJ
Nathan Speare Regional Burn Treatment Center, Crozer Chester Medical Center, Upland, PA 19104-4495, USA. m.cawley@usip.edu
Braxton
G R
GR
Haith
L R
LR
Reilly
K J
KJ
Guilday
R E
RE
Patton
M L
ML
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002056:Burns / Q000382:microbiology*; D002408:Catheters, Indwelling / Q000382:microbiology; D004352:Drug Resistance, Microbial; D017809:Fatal Outcome; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use; D016469:Fungemia / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009181:Mycoses / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D014250:Trichosporon / Q000187:drug effects; D014946:Wound Infection / Q000188:drug therapy*
D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine